|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identify mammalian target of rapamycin (mTOR) as potentially valuable target for EGFR mutant lung cancer. mTOR is activated in human lung cancers with EGFR mutations, and this increases with acquisition of T790M mutation.
|
24931608 |
2014 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.
|
31393074 |
2019 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Peripheral blood sampling for detection of EGFR T790M in cell-free circulating tumour (ct) DNA in TKI-resistant EGFR mutant (EGFRm) lung cancer is now standard.
|
31027703 |
2019 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
|
27891677 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
|
21135146 |
2011 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
OBX1-012 treatment was highly effective against human EGFR-mutant lung cancer models with or without EGFR T790M, not only in vitro but also in vivo.
|
29754184 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
We developed experimental brain metastasis models by intraventricular injection (intraventricular injection mouse model; IVM) of HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung cancer (NCI-H1975-luc) cells.
|
29321587 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer.
|
30333118 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cell line-based assays showed that Aki1 constitutively associates with mutant EGFR in lung cancer cells with (H1975) or without (PC-9 and HCC827) T790M gatekeeper mutation.
|
23045273 |
2013 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer.
|
26152920 |
2015 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.
|
25074459 |
2014 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we demonstrate that apigenin combined with gefitinib inhibits multiple oncogenic drivers such as c-Myc, HIF-1α, and EGFR, reduces Gluts and MCT1 protein expression, and inactivates the 5' adenosine monophosphate-activated protein kinase (AMPK) signaling, which regulates glucose uptake and maintains energy metabolism, leading to impaired energy utilization in EGFR L858R-T790M-mutated H1975 lung cancer cells.
|
30967777 |
2019 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, the combination of new generation EGFR TKIs and SAHA may be a new strategy to overcome the acquired resistance to EGFR TKIs in T790M mutant lung cancer.
|
25382705 |
2015 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.
|
29963252 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Therefore, germline <i>EGFR</i> T790M mutations result in a unique inherited lung cancer syndrome targeting never smokers.
|
30225213 |
2018 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, a low gefitinib dose caused tumors to become drug-resistant prior to acquisition of the T790M mutation or MET amplification in EGFR-mutated models of lung cancer.
|
24033722 |
2013 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of low-level EGFR T790M mutation in lung cancer tissues.
|
21635547 |
2011 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, osimertinib 80 mg demonstrated statistically significant improvement in the objective response rate, which was comparable to those in the nonelderly population.Osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation; further research in larger scale is warranted.
|
30651400 |
2019 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notably, the patient with EGFR-T790M germline mutation had multiple maternal family members diagnosed with lung cancers, strongly supporting its role in inherited lung cancer.
|
30610926 |
2019 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study established lung cancer cell lines that were resistant to gefitinib or erlotinib, and these cell lines were verified to contain the <i>EGFR</i> T790M mutation.
|
28781659 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Serial plasma genotyping of EGFR-mutant lung cancer on erlotinib demonstrated pretreatment detection of EGFR mutations, complete plasma response in most cases, and increasing levels of EGFR T790M emerging before objective progression.
|
24429876 |
2014 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.
|
15737014 |
2005 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This review summarizes information about and current treatment strategies for patients with EGFR-mutant lung cancer whose disease progresses on their initial EGFR inhibitor, including those with T790M and other types of acquired resistance.
|
27196961 |
2016 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations.
|
28620690 |
2017 |
|
rs121434569
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib-a third-generation EGFR-TKI-targets the T790M mutation and has demonstrated high efficacy against <i>EGFR</i>-mutated lung cancer.
|
30445769 |
2018 |